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Gold(III) complexes with  different L-histidine-containing dipeptides, [Au(Gly-L-His-
NA,NP,N3)Cl]Cl.3H2O (1a), [Au(Gly-L-His-NA,NP,N3)Cl]NO3.1.25H2O (1b), [Au(L-Ala-L-
His-NA,NP,N3)Cl][AuCl4].H2O (2a), [Au(L-Ala-L-His-NA,NP,N3)Cl]NO3.2.5H2O (2b), 
[Au(L-Val-L-His-NA,NP,N3)Cl]Cl.2H2O (3), [Au(L-Leu-L-His-NA,NP,N3)Cl]Cl (4a) and 
[Au(L-Leu-L-His-NA,NP,N3)Cl][AuCl4].H2O (4b) have been synthesized and structurally 
characterized by spectroscopic (1H NMR, IR and UV-vis) and single-crystal X-ray 
diffraction techniques. The antimicrobial efficiency of these gold(III) complexes, along 
with K[AuCl4] and the corresponding dipeptides, was evaluated against the broad panel of 
Gram-positive and Gram-negative bacteria and fungi, displaying their moderate inhibiting 
activity. Moreover, cytotoxic properties of the investigated complexes were assessed 
against the normal human lung fibroblast cell line (MRC5) and two human cancer, cervix 
(HeLa) and lung (A549) cell lines. None of the complexes exerted significant cytotoxic 
activity; nevertheless complexes that did show selectivity in terms of cancer vs. normal cell 
lines (2a/b and 4a/b) have been evaluated using zebrafish (Danio rerio) embryos for 
toxicity and antiangiogenic potential. Although the gold(III) complexes achieved 
antiangiogenic effect comparable to the known angiogenic inhibitors auranofin and 
sunitinib malate at 30-fold higher concentrations, they had no cardiovascular side effects, 
which commonly accompany auranofin and sunitinib malate treatment.  Finally, binding of 
the gold(III) complexes to the active sites of both human and bacterial (Escherichia coli) 
thioredoxin reductases (TrxRs) was demonstrated by molecular docking study, suggesting 
that the mechanism of biological action of these complexes can be associated with their 
interaction with the TrxR active site. 
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Fig. S1 The dose-dependent inhibition of the subintestinal vessels (SIVs) 
formation in zebrafish embryos after 48 h of treatments with gold(III)-peptide 
complexes 2a, 2b, 4a and 4b. Normally developed SIVs basket with 5 - 9 vessels 
is denoted in DMSO-treated embryo (dashed circle). Reduction in the size and the 
number of vessels of SIVs basket upon different treatments are designed with 
arrowhead. Auranofin (1.25 μM) and sunitinib malate (1.25 μM) are used as 
positive controls, upon which regimes embryos suffered of pericardial edemas 
(arrow).
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Fig. S2 The best docking pose for the corresponding gold(III) complex cation and 
auranofin inside human thioredoxin reductase active site.
S6
Fig. S3 LigPlot diagrams illustrating interactions between the corresponding gold 
complexes and human thioredoxin reductase during docking. Hydrogen bonds are 
illustrated by dashed lines and the donor-acceptor distances are given in Å units. 
Hydrophobic interactions are represented by red spokes radiating towards the 
ligand atoms they contact. Amino acids labeled in black form hydrophobic and 
van der Walls interactions, while those labeled in green form hydrogen bonds with 
the complex. The interacted atoms are spokes radiating back. C, N, O, S and Au 
atoms are represented in black, blue, red, yellow and green, respectively. 
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Fig. S4 The best docking pose for the corresponding gold(III) complex cation and 
auranofin inside Escherichia coli thioredoxin reductase active site.
S14
Fig. S5 LigPlot diagrams illustrating interactions between the corresponding gold 
complexes and Escherichia coli thioredoxin reductase during docking. Hydrogen 
bonds are illustrated by dashed lines and the donor-acceptor distances are given in 




the ligand atoms they contact. Amino acids labeled in black form hydrophobic and 
van der Walls interactions, while those labeled in green form hydrogen bonds with 
the complex. The interacted atoms are spokes radiating back. C, N, O, S and Au 
atoms are represented in black, blue, red, yellow and green, respectively.
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Fig. S1 The dose-dependent inhibition of the subintestinal vessels (SIVs) formation in 
zebrafish embryos after 48 h of treatments with gold(III)-peptide complexes 2a, 2b, 4a and 
4b. Normally developed SIVs basket with 5 - 9 vessels is denoted in DMSO-treated 
embryo (dashed circle). Reduction in the size and the number of vessels of SIVs basket 
upon different treatments are designed with arrowhead. Auranofin (1.25 μM) and sunitinib 




Fig. S2 The best docking pose for the corresponding gold(III) complex cation and 












Fig. S3 LigPlot diagrams illustrating interactions between the corresponding gold 
complexes and human thioredoxin reductase during docking. Hydrogen bonds are 
illustrated by dashed lines and the donor-acceptor distances are given in Å units. 
Hydrophobic interactions are represented by red spokes radiating towards the ligand atoms 
they contact. Amino acids labeled in black form hydrophobic and van der Walls 
interactions, while those labeled in green form hydrogen bonds with the complex. The 
interacted atoms are spokes radiating back. C, N, O, S and Au atoms are represented in 
















Fig. S4 The best docking pose for the corresponding gold(III) complex cation and 












Fig. S5 LigPlot diagrams illustrating interactions between the corresponding gold 
complexes and Escherichia coli thioredoxin reductase during docking. Hydrogen bonds are 
illustrated by dashed lines and the donor-acceptor distances are given in Å units. 
Hydrophobic interactions are represented by red spokes radiating towards the ligand atoms 
they contact. Amino acids labeled in black form hydrophobic and van der Walls 
interactions, while those labeled in green form hydrogen bonds with the complex. The 
interacted atoms are spokes radiating back. C, N, O, S and Au atoms are represented in 
























































































































































































Table S3 Hydrogen bond parameters (Å , °)
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) Symmetry operations on A
[Au(Gly-L-His-NA,NP,N3)Cl]Cl·3H2O
(1a)1
O3—H11···O5 0.97 1.66 2.618 174
N1—H1···Cl2 0.95 2.21 3.150 170
N1—H2···O6 0.94 1.84 2.776 171
N4—H9···O4 0.95 1.84 2.758 161
C7—H10···O2 0.96 2.44 3.173 133 -x+1,+y+1/2,-z
[Au(Gly-L-His-NA,NP,N3)Cl]NO3·1.25H2O
(1b)2
O3—H3OO1N 0.82 2.03 2.680(15) 135
N1—H1NO2W 0.90 2.07 2.961(14) 171 x-1/2,+y+1/2,+z
N1—H2NO1 0.90 2.16 2.876(18) 136 -x+1/2+1,+y-1/2,-z+2
N1—H2NCl1’ 0.90 2.82 3.491(18) 133 x,+y-1,+z
N4—H4NO4N 0.86 2.52 3.231(19) 141
N4—H4NO6N 0.86 2.08 2.901(21) 159
C6—H6O3 0.93 2.65 3.397(18) 138 -x+2,+y,-z+2
C7—H7O2’ 0.93 2.40 3.317(19) 168
O3’—H3O’O1W 0.82 1.92 2.709(18) 162
N1’—H1N’O2W 0.90 2.05 2.932(15) 166 x-1/2,+y+1/2,+z
N1’—H2N’O5N 0.90 2.11 2.971(16) 161 x-1/2,+y+1/2,+z
N1’—H2N’O1’ 0.90 2.68 3.202(15) 118 -x+1/2+1,+y+1/2,-z+1
N4’—H4N’O1N 0.86 2.00 2.849(16) 170 -x+2,+y,-z+2
Electronic Supplementary Information
S26
N4’—H4N’O2N 0.86 2.56 3.062(17) 118 -x+2,+y,-z+2
C6’—H6’O2N 0.93 2.61 3.098(22) 113 -x+2,+y,-z+2
C7’—H7’O2 0.93 2.33 3.108(17) 141
[Au(L-Ala-L-His-NA,NP,N3)Cl][AuCl4]·H2O
(2a)
O3—H3OO1W 0.82 1.81 2.620(7) 170
N1—H1AO1 0.89 1.98 2.824(8) 159 -x+1/2+1,+y-1/2,-z+1
N1—H1BCl5 0.89 2.48 3.364(6) 173
N4—H4Cl2 0.86 2.61 3.358(10) 146 x,+y,+z+1
N4—H4Cl2 0.86 2.72 3.279(10) 124 -x+1,+y,-z+1
C7—H7Cl5 0.93 2.97 3.562(10) 123 x,+y,+z+1
O1W—H1WO1 0.82 2.00 2.823(9) 179 x,+y,+z+1
O1W—H2WO2 0.82 2.05 2.868(11) 180 -x+1/2+1,+y+1/2,-z+2
[Au(L-Ala-L-His-NA,NP,N3)Cl]NO3·2.5H2O
(2b)2 
O3—H3OO1W 0.82 1.85 2.653(14) 168
N1—H1NO2W 0.90 2.00 2.887(9) 170
N1—H2NO3W 0.90 2.26 3.142(14) 165
N4—H4NO1N 0.86 2.52 3.189(21) 135
N4—H4NO2N 0.86 1.96 2.808(19) 170
N4—H4NO1N’ 0.86 2.08 2.890(29) 157
N4—H4NO3N’ 0.86 2.33 3.069(38) 144
C6—H6O1W 0.93 2.83 3.489(11) 128 -x+1/2+1,+y-1/2,-z+1





O3—H3AO4W 0.82 1.80 2.534(16) 148 x,+y,+z-1
N1—H1AO2W 0.89 1.94 2.810(13) 167
N1—H1BO1W 0.89 2.16 2.922(15) 143
N4—H4Cl4 0.86 2.20 3.040(9) 167
C7—H7O22 0.93 2.27 3.170(12) 162
O23—H23AO3W 0.82 1.80 2.611(13) 171
N21—H21AO2W 0.89 1.94 2.808(10) 166
N21—H21BO1W 0.89 2.30 3.010(11) 137 x-1,+y,+z
N24—H24Cl3 0.86 2.24 3.072(15) 162
O1W—H11WCl3 0.82 2.38 3.202(8) 180 x+1,+y+1,+z
O1W—H12WCl4 0.82 2.36 3.166(9) 169 x,+y+1,+z
O2W—H21WCl3 0.82 2.24 3.054(8) 170 x,+y+1,+z
O2W—H22WCl4 0.82 2.28 3.062(11) 158 x,+y+1,+z
O3W—H31WCl4 0.82 2.37 3.177(11) 167
O3W—H32WO1 0.82 1.93 2.749(11) 180 x,+y-1,+z+1
O3W—H42WO21 0.82 1.91 2.730(14) 180
O4W—H41WCl3 0.82 2.43 3.197(9) 157 x,+y,+z+1
[Au(L-Leu-L-His-NA,NP,N3)Cl]Cl
(4a)
O3—H3OCl2 0.82 2.26 3.079(5) 176
N1—H1AO2 0.89 2.19 2.879(9) 134 -x+1,+y-1/2,-z+1/2
N1—H1ACl2 0.89 2.68 3.365(6) 134 -x+1,+y-1/2,-z+1/2
N1—H1BCl2 0.89 2.51 3.356(6) 160 x,+y-1,+z
N4—H4Cl2 0.86 2.39 3.167(6) 151 -x+2,+y-1/2,-z+1/2
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C3—H3O1 0.98 2.32 2.728(9) 104
C6—H6Cl1 0.93 2.68 3.549(8) 156 -x+2,+y+1/2,-z+1/2
C7—H7O1 0.93 2.59 3.441(9) 152 -x+1/2+1,-y+1,+z-1/2
[Au(L-Leu-L-His-NA,NP,N3)Cl][AuCl4]·H2O
(4b)
O3—H3AO1 0.82 1.91 2.718(9) 167 -x+2,+y+1/2,-z+1/2+1
N1—H1AO1W 0.89 1.82 2.701(8) 174
N1—H1BCl5 0.89 2.44 3.323(6) 171
N4—H4Cl4 0.86 2.88 3.563(7) 138 x,+y+1,+z
N4—H4Cl5 0.86 2.65 3.372(7) 142 x,+y+1,+z
C7—H7Cl1 0.93 2.73 3.169(9) 110
C7—H7Cl2 0.9 2.87 2.484(9) 125 x-1/2,-y+1/2+1,-z+1
O1W—H1WCl4 0.82 2.56 3.375(7) 180 x-1/2,-y+1/2,-z+1
O1W—H2WO2 0.82 2.03 2.787(9) 153 -x+1,+y-1/2,-z+1/2+1
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Table S4 Score values (kcal/mol) for all studied gold complexes for both human and Escherichia coli thioredoxin reductases (TrxRs)







1a/b -10.3001 -15.7147 -97.6026 -28.3324 -107.792 -117.767 -93.4174 -6.34069 -5.49514
2a/b -8.28748 -12.987 -100.515 8.58733 -100.891 -113.659 -67.7239 -5.60504
3 -8.83728 -20.0669 -102.647 -10.8993 -110.66 -128.054 -83.9307 -5.53298
-3.76244
-4.19654
4a/b -8.24472 -19.3412 -112.94 -20.772 -114.527 -131.499 -90.69 -5.45368 -4.31857
auranofin -15.0274 -26.5616 -146.155 21.3618 -153.482 -143.236 -82.942 -4.95102 -2.67555
E. coli TrxR
1a/b -10.518 -19.1302 -95.1559 -13.3679 -101.493 -117.791 -76.8644 -5.97016 -4.52143
2a/b -9.44207 -13.5791 -98.9944 34.371 -100.694 -112.804 -52.7091 -5.5941 -2.92828
3 -3.58192 -16.8204 -106.373 5.59057 -111.03 -133.064 -77.7934 -5.55152
4a/b -4.85869 -15.3973 -116.986 -25.9755 -112.269 -132.434 -90.7863 -5.34613
-3.88967
-4.32316
auranofin -4.83363 -12.0032 -175.936 -44.9353 -167.046 -172.59 -129.802 -5.38859 -4.18717
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Table S5 Crystallographic data collection and structure refinement information for gold(III) complexes 2a, 3, 4a and 4b
2a 3 4a 4b
Crystal data
Chemical formula C9H15Au2Cl5N4O4 C11H21AuCl2N4O5 C12H19AuCl2N4O3 C12H21Au2Cl5N4O4
Mr 814.43 557.18 535.18 856.51
Crystal system, space group Monoclinic, C2 Triclinic, P1 Orthorhombic, P212121 Orthorhombic, P212121
a, b, c (Å) 27.3091(7), 8.6678(2), 8.6743(2) 6.9310(4), 11.7421(7), 12.5963(8) 9.8509(2), 10.7911(2), 15.3736(3) 8.3519(1), 11.1268(1), 24.3707(2)
, ,  (°) 90, 108.081(2), 90 68.927(6), 79.453(5), 88.221(5) 90, 90, 90 90, 90, 90
V (Å3) 1951.90(8) 939.75(11) 1634.25(6) 2264.77(4)
Z 4 2 4 4
 (mm-1) 15.72 8.14 9.35 13.56
Crystal size (mm) 0.45 × 0.35 × 0.35 0.45 × 0.20 × 0.13 0.20 × 0.15 × 0.15 0.25 × 0.10 × 0.07
Data collection
Tmin, Tmax 0.019, 0.070 0.105, 0.532 0.300, 0.505 0.113, 0.528
No. of measured, independent and
 observed [I> 2(I)] reflections
18553, 3462, 3403  21633, 6620, 6230  18637, 2895, 2795  40694, 3993, 3835  
Rint 0.038 0.028 0.040 0.038
(sin /)max (Å-1) 0.595 0.595 0.595 0.595
Refinement
R[F2> 2(F2)], wR(F2), S 0.017,  0.042,  1.09 0.023,  0.055,  1.06 0.019,  0.039,  1.03 0.018,  0.041,  1.05
No. of reflections 3462 6620 2895 3993
No. of parameters 220 421 203 245
No. of restraints 1 3 0 0
Δmax, Δmin (e Å-3) 0.70, -0.61 0.90, -0.48 0.62, -0.39 0.66, -0.76
Absolute structure parameter -0.025(4) -0.012(4) -0.016(5) -0.015(3)
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Table S6 Lethal and teratogenic effects observed in zebrafish (Danio rerio) embryos at 
different hours post fertilization (hpf)
Category Developmental endpoints Exposure time (hpf)
24 48 72 96/114
Lethal effect Egg coagulationa ● ● ● ●
No somite formation ● ● ● ●
Tail not detached ● ● ● ●
No heartbeat ● ● ●
Teratogenic effect Malformation of head ● ● ● ●
Malformation of eyesb ● ● ● ●
Malformation of 
sacculi/otolithsc ● ● ● ●
Malformation of chorda ● ● ● ●
Malformation of taild ● ● ● ●
Scoliosis ● ● ● ●
Heartbeat frequency ● ● ●
Blood circulation ● ● ●
Pericardial edema ● ● ● ●
Yolk edema ● ● ● ●
Yolk deformation ● ● ● ●
Growth retardatione ● ● ● ●
aNo clear organs structure is recognized.
bMalformation of eyes was recorded for the retardation in eye development and abnormality in  shape and size.
cPresence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement of otoliths 
and/or sacculi (otic vesicles).
dTail malformation was recorded when the tail was bent, twisted or shorter than to control embryos as assessed 
by optical comparation.
eGrowth retardation was recorded by comparing with the control embryos in development or size (before 
hatching, at 24 hpf and 48 hpf) or in a body length (after hatching, at and onwards 72 hpf) using by optical 




1 M. Wienken, B. Lippert, E. Zangrando and L. Randaccio, Inorg. Chem., 1992, 31, 
1983-1985.
2 U. Rychlewska, B. Warżajtis, B. Đ. Glišić, M. D. Živković, S. Rajković and M. I. 
Djuran, Dalton Trans., 2010, 39, 8906-8913.
